RNS & Investor News

Extension of territories for GoFigure® with Extensor

24 March 2020

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has extended the territories of its original distribution agreements with Extensor Robert Buczek ("Extensor") to distribute OptiBiotix's own label GoFigure® consumer weight management products in Ukraine, Estonia, Lithuania, Latvia, Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan, Turkmenistan, Armenia, Azerbaijan, Georgia, Belarus, Moldova and Russia.

Extensor is OptiBiotix's exclusive partner in Poland for distributing its GoFigure® product range (RNS: 22 May 2019) and SlimBiome® (RNS: 6 December 2019). The signing of an amendment to the agreement granting Extensor exclusive rights to distribute GoFigure® into additional territories highlights the positive evolution of the GoFigure® and SlimBiome® distribution agreements. The deal will create new commercial opportunities in new territories which may generate revenues with the commercialisation of the GoFigure® range on new online platforms such as Domo in Ukraine: https://domo.co.ua/search?string=Gofigure&category=all.

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to strengthen our partnership with Extensor to distribute our GoFigure® range beyond the Polish borders as they have proven to be a very reliable commercial partner and have recently placed additional orders for GoFigure® branded products to replenish their stocks. The signing of a territory extension amendment to the original agreement shows a positive evolution of the relationship and increases the global reach of our trademarks thus contributing to increasing the value of our portfolio of trademarks."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy

 

Latest RNS News

Extension of territories for GoFigure® with Extensor

24 March 2020

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has extended the territories of its original distribution agreements with Extensor Robert Buczek ("Extensor") to distribute OptiBiotix's own label GoFigure® consumer weight management products in Ukraine, Estonia, Lithuania, Latvia, Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan, Turkmenistan, Armenia, Azerbaijan, Georgia, Belarus, Moldova and Russia.

Extensor is OptiBiotix's exclusive partner in Poland for distributing its GoFigure® product range (RNS: 22 May 2019) and SlimBiome® (RNS: 6 December 2019). The signing of an amendment to the agreement granting Extensor exclusive rights to distribute GoFigure® into additional territories highlights the positive evolution of the GoFigure® and SlimBiome® distribution agreements. The deal will create new commercial opportunities in new territories which may generate revenues with the commercialisation of the GoFigure® range on new online platforms such as Domo in Ukraine: https://domo.co.ua/search?string=Gofigure&category=all.

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to strengthen our partnership with Extensor to distribute our GoFigure® range beyond the Polish borders as they have proven to be a very reliable commercial partner and have recently placed additional orders for GoFigure® branded products to replenish their stocks. The signing of a territory extension amendment to the original agreement shows a positive evolution of the relationship and increases the global reach of our trademarks thus contributing to increasing the value of our portfolio of trademarks."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy